These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 38053615)
21. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062 [TBL] [Abstract][Full Text] [Related]
22. Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. Klavdianou K; Lazarini A; Grivas A; Tseronis D; Tsalapaki C; Rapsomaniki P; Antonatou K; Thomas K; Boumpas D; Katsimbri P; Vassilopoulos D Front Med (Lausanne); 2020; 7():288. PubMed ID: 32637422 [No Abstract] [Full Text] [Related]
23. Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort. Tillett W; Birt J; Cavanaugh C; Jung Y; Vadhariya A; Ross S; Paulus J; Lubrano E Front Med (Lausanne); 2023; 10():1184028. PubMed ID: 37415769 [TBL] [Abstract][Full Text] [Related]
24. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab. Kiltz U; Sfikakis PP; Gaffney K; Bounas A; Gullick N; Lespessailles E; Brandt-Juergens J; Rashkov R; Schulz B; Pournara E; Jagiello P Rheumatol Ther; 2022 Aug; 9(4):1129-1142. PubMed ID: 35674938 [TBL] [Abstract][Full Text] [Related]
25. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement. Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254 [TBL] [Abstract][Full Text] [Related]
27. Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study. Galluzzo M; Trovato E; Talamonti M; Caldarola G; Di Nardo L; Lazzeri L; Mugheddu C; Burlando M; Balestri R; Bernardini N; Biondi G; Vellucci L; Russo F; De Simone C; Paganini C; Rech G; Cozzani EC; Atzori L; Montesu MA; Potenza C; Chiricozzi A; Rubegni P J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999429 [No Abstract] [Full Text] [Related]
28. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required? Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235 [TBL] [Abstract][Full Text] [Related]
29. Treatment persistence of biologics among patients with psoriatic arthritis. Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410 [TBL] [Abstract][Full Text] [Related]
30. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. Colombo D; Frassi M; Pagano Mariano G; Fusaro E; Lomater C; Del Medico P; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Grassi W; Grembiale RD; Guggino G; Mazzone A; Tirri E; Perricone R; Sarzi Puttini PC; De Vita S; Conti F; Ori A; Simoni L; Fiocchi M; Orsenigo R; Zagni E; BMC Rheumatol; 2022 Sep; 6(1):57. PubMed ID: 36089612 [TBL] [Abstract][Full Text] [Related]
31. Long-term remission and biologic persistence rates: 12-year real-world data. Murray K; Turk M; Alammari Y; Young F; Gallagher P; Saber T; Fearon U; Veale DJ Arthritis Res Ther; 2021 Jan; 23(1):25. PubMed ID: 33441191 [TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. Schweikert B; Malmberg C; Åkerborg Ö; Kumar G; Nott D; Kiri S; Sapin C; Hartz S Pharmacoecon Open; 2020 Dec; 4(4):635-648. PubMed ID: 32166657 [TBL] [Abstract][Full Text] [Related]
33. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor. Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296 [TBL] [Abstract][Full Text] [Related]
34. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study. Joven B; Hernández Sánchez R; Pérez-Pampín E; Aragón Díez Á; Almodóvar R; Martínez-Ferrer Á; Belzunegui J; Rubio E; Díaz-Cerezo S; Moyano S; Gómez-Barrera M; Yébenes M; Núñez M Rheumatol Ther; 2023 Oct; 10(5):1319-1333. PubMed ID: 37481752 [TBL] [Abstract][Full Text] [Related]
35. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Sunar I; Ataman S; Nas K; Kilic E; Sargin B; Kasman SA; Alkan H; Sahin N; Cengiz G; Cuzdan N; Gezer IA; Keskin D; Mülkoğlu C; Resorlu H; Bal A; Duruöz MT; Küçükakkaş O; Yurdakul OV; Melikoglu MA; Aydın Y; Ayhan FF; Bodur H; Calis M; Capkın E; Devrimsel G; Gok K; Hizmetli S; Kamanlı A; Keskin Y; Kocabas H; Kutluk O; Şen N; Şendur OF; Tekeoğlu I; Tolu S; Toprak M; Tuncer T Rheumatol Int; 2020 Feb; 40(2):283-294. PubMed ID: 31773391 [TBL] [Abstract][Full Text] [Related]
36. [A new integral enthesial-comorbididity index of psoriatic arthritis activity]. Korsakova YL; Korotaeva TV; Loginova EY; Gubar EE; Vorobyeva LD; Glukhova SI; Nasonov EL Ter Arkh; 2023 Jul; 95(5):404-409. PubMed ID: 38158993 [TBL] [Abstract][Full Text] [Related]
37. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA. Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473 [TBL] [Abstract][Full Text] [Related]
39. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751 [No Abstract] [Full Text] [Related]
40. Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study. Kirkham B; Nash P; Reina D; Navarra S; Quebe-Fehling E; Gaillez C; Sastre C; Mease PJ Clin Exp Rheumatol; 2023 Mar; 41(3):589-596. PubMed ID: 35916290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]